CAMPAIGN CORRESPONDENCE


  • Blood Cancer

    31 October 2019

    Dear Constituent,

    Thank you for contacting me about blood cancers.

    With around 13,000 people dying from leukaemia, lymphoma, or myeloma each year across the UK, please allow me to assure you that improving outcomes for patients diagnosed with blood cancers remains a key NHS priority.

    Early diagnosis of blood cancers can be difficult with symptoms, for example back pain, bruising, or tiredness, often misdiagnosed. That is why I am glad that guidance for clinicians on diagnosing blood cancer has been set out by the National Institute for Health and Care Excellence (NICE). I support moves to raise awareness of these symptoms and the NICE Guidance. I am delighted that the £200 million announced in transformation funding to encourage new and innovative ways to diagnose cancer earlier will help to speed up diagnosis of blood cancers.

    Stem cell transplants are a key treatment for blood cancers, with over 2,000 people a year across the UK requiring a bone marrow or stem cell transplant. As such I am pleased that a unified UK stem cell registry has been established – the Anthony Nolan and NHS Stem Cell Registry – streamlining the provision of stem cells for transplant. This has helped increase the number of registered blood stem cell donors from 770,000 in 2010 to over 1.4 million as of 2017. 

    The NHS Long Term Plan (LTP), published in January 2019, commits to improving detection, with more targeted screening and Rapid Access Diagnostic Centres, so that in 10 years’ time these measures will help achieve 55,000 more people surviving cancer each year. 

    I am confident that continued investment into ways of diagnosing blood cancers earlier, as well as increasing the pool of available stem cell donors, will help to drive up survival rates of leukaemia, lymphoma, and myeloma up even further.

    Thank you again for taking the time to contact me.

    Yours sincerely,



    Mel Stride MP

    MP for Central Devon







CONTACT DETAILS: